Together, the data show that suppression of GBM growth through combination S6K1 and AXL targeting is achieved by preventing the activation of upstream AXL under feedback control by S6K2, which is sufficient to sustain GBM pyrimidine biosynthesis and growth. Here, AXL is linked to glioblastoma.